MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Operating Expenses 2011-2026 | NDRA
Annual Operating Expenses ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.76 M | 10.8 M | 10.5 M | 13.2 M | 11.5 M | - | 10.8 M | 8.74 M | 4.8 M | 2.07 M | 2.31 M | 1.83 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.2 M | 1.83 M | 7.49 M |
Quarterly Operating Expenses ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 M | 1.3 M | 1.47 M | - | 1.51 M | 2.23 M | 2.78 M | - | 3.13 M | 2.99 M | 2.94 M | - | 3.42 M | 3.57 M | 2.86 M | - | 2.65 M | 3.2 M | 2.58 M | - | 3.26 M | 2.89 M | 3.1 M | - | 2.64 M | 2.33 M | 2.75 M | - | 2.36 M | 1.82 M | 2.84 M | - | 1.08 M | 1.06 M | 361 K | - | 605 K | 494 K | 373 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.57 M | 361 K | 2.2 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
726 M | $ 16.79 | -2.33 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
411 M | $ 20.96 | - | $ 1.12 B |  USA |
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
50.6 M | $ 1.6 | 1.91 % | $ 2.13 M | USA |
 |
Castle Biosciences
CSTL
|
59.5 M | $ 24.98 | -2.14 % | $ 694 M | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 14.61 | -3.37 % | $ 442 M | USA |
 |
Agilent Technologies
A
|
1.99 B | $ 115.92 | 3.45 % | $ 35.2 B | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 113.13 | 1.04 % | $ 9.33 B |  Irlanda |
 |
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
123 M | $ 86.87 | -1.04 % | $ 5.86 B | USA |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
3.69 B | $ 137.52 | -1.33 % | $ 21.9 B | USA |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.95 | 0.1 % | $ 458 M | USA |
 |
NeoGenomics
NEO
|
430 M | $ 8.95 | -0.56 % | $ 1.15 B | USA |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
38.5 M | $ 18.52 | 1.65 % | $ 415 M | USA |
 |
Medpace Holdings
MEDP
|
118 M | $ 421.13 | 0.99 % | $ 12.1 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 26.56 | 1.22 % | $ 20 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
607 M | $ 175.79 | 2.0 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Personalis
PSNL
|
44.5 M | $ 5.76 | -2.46 % | $ 341 M | USA |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
226 M | $ 89.53 | -1.8 % | $ 11.2 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
20 M | $ 2.0 | -5.66 % | $ 8.85 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.15 B | $ 465.11 | 0.56 % | $ 175 B | USA |
 |
Senseonics Holdings
SENS
|
61.8 M | $ 4.86 | -2.99 % | $ 203 M | USA |
 |
Soleno Therapeutics
SLNO
|
181 M | $ 52.92 | 0.03 % | $ 2.69 B | USA |
 |
Twist Bioscience Corporation
TWST
|
116 M | $ 58.02 | 3.25 % | $ 3.47 B | USA |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
5.64 M | $ 2.19 | 1.38 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 254.31 | 0.52 % | $ 21.2 B | USA |
 |
Celcuity
CELC
|
172 M | $ 143.61 | -0.94 % | $ 6.71 B | USA |
 |
Natera
NTRA
|
258 M | $ 210.69 | -0.41 % | $ 20.7 B | USA |
 |
Neogen Corporation
NEOG
|
1.48 B | $ 9.28 | 2.04 % | $ 2.01 B | USA |
 |
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 190.85 | -0.38 % | $ 21.2 B | USA |
 |
Waters Corporation
WAT
|
687 M | $ 338.34 | 12.22 % | $ 20.1 B | USA |